XML 20 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Operating activities    
Net income (loss) $ 89,954 $ (118,598)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
Depreciation and amortization 2,694 1,829
Stock-based compensation expense 14,550 22,359
Impairment of out-license asset and remeasurement of CVR liability, net 6,772  
Loss on debt extinguishment 12,630  
Gain on Sale Transaction, net (Note 6) (177,732)  
Inventory write-downs, net 2,481 2,894
Other non-cash adjustments, net (1,267) (556)
Changes in operating assets and liabilities:    
Trade receivables, net 85,217 (31,350)
Inventory (18,557) (15,715)
Prepaid manufacturing 7,170 302
Other prepaid, current and non-current assets (4,249) 4,785
Accounts payable 40,077 17,786
Accrued rebates, fees and reserves 6,523 26,383
TSA related operating assets and liabilities, net (Note 6) (4,781)  
Accrued compensation (2,643) (8,472)
Accrued and other current and non-current liabilities (45,871) (9,294)
Net cash provided by (used in) operating activities 12,968 (107,647)
Investing activities    
Purchases of investments in marketable securities   (19,507)
Proceeds from maturities of investments in marketable securities 6,200 64,750
Proceeds from sale of investments in marketable securities 8,688 13,282
Milestone based license fee payment to Junshi Biosciences (12,500)  
Other investing activities, net 208 366
Net cash provided by investing activities 230,419 58,891
Financing activities    
Proceeds from 2029 Term Loan, net of debt discount & issuance costs 37,120  
Proceeds from Revenue Purchase and Sale Agreement, net of issuance costs 36,495  
Proceeds from issuance of common stock upon exercise of stock options 291 117
Proceeds from purchase under the employee stock purchase plan 685 1,337
Taxes paid related to net share settlement (2,456) (3,086)
Repayment of 2027 Term Loans, premiums and exit fees (260,387)  
Other financing activities (241) (625)
Net cash (used in) provided by financing activities (187,038) 58,129
Net increase in cash, cash equivalents and restricted cash 56,349 9,373
Cash, cash equivalents and restricted cash at beginning of period 103,343 63,987
Cash, cash equivalents and restricted cash at end of period 159,692 73,360
Supplemental disclosures of non-cash activities    
Non-cash employee bonuses settled in common stock 4,408  
Financing issuance costs in accrued and other current liabilities 1,008  
CIMERLI Sale    
Investing activities    
Cash received from Sale 187,823  
YUSIMRY Sale    
Investing activities    
Cash received from Sale 40,000  
At The Market Offering.    
Financing activities    
Proceeds from issuance of common stock, net of issuance costs $ 1,455 6,761
Public Offering    
Financing activities    
Proceeds from issuance of common stock, net of issuance costs   $ 53,625